5 June, 2021

Ally Bridge Portfolio News – GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test

— Galleri’s ability to detect more than 50 types of cancer with a single blood draw could transform early cancer detection as a complement to existing screenings; test now available in U.S. by prescription only — MENLO PARK, Calif., June 4, 2021 — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, […]

Read More
6 May, 2021

Ally Bridge Portfolio News – Vida Health raises $110M in Series D round led by General Atlantic, Centene, and AXA Venture Partners

New capital to help Vida continue to scale virtual chronic mental and physical healthcare services after tripling revenue in 2020 Led by General Atlantic, the $110M Series D fundraise will help Vida continue to expand its network of providers, deepen its machine learning capabilities, broaden its commercial efforts, and provide more people the care they […]

Read More
28 April, 2021

Ally Bridge Portfolio News – Ultivue Announces $50M Financing Round

April 27, 2021 10:07 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE) –Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing. New investors include Ally Bridge Group, Pura Vida […]

Read More
16 March, 2021

Ally Bridge Portfolio News – Rapid Micro Biosystems Raises $81M to Continue Global Expansion of Automated Pharmaceutical QC Platform to Improve Data Integrity and Safety in Biologics, Vaccines, and Cell & Gene Therapy Manufacturing

LOWELL, Mass., March 16, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc., the leading provider of data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, today announced the completion of an $81 million equity financing. The funding round was led by new investor D1 Capital Partners, along with funds and accounts managed by […]

Read More
3 March, 2021

RefleXion Adds Ally Bridge Group to Investor Syndicate

Expands Series D financing by $40M March 02, 2021 10:00 AM Eastern Standard Time HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, today announced the successful completion of a $40 million extension to its Series D financing, which combined with $110 million raised […]

Read More
17 February, 2021

ABG Acquisition Corp. I Announces Pricing of Upsized $131 Million Initial Public Offering

NEW YORK and HONG KONG, Feb. 16, 2021 /PRNewswire/ — ABG Acquisition Corp. I (the “Company”) today announced the pricing of its initial public offering of 13,100,000 Class A ordinary shares at a price of $10.00 per share. The shares will be listed on The Nasdaq Capital Market and trade under the ticker symbol “ABGI” […]

Read More
16 February, 2021

Ally Bridge Group Co-leads Mainstay Medical’s $108 Million Equity Financing

Funding to support U.S. commercial launch and global expansion February 16, 2021 08:00 AM Eastern Standard Time DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing of an equity financing in which it raised gross proceeds of US$108 million. Mainstay intends to use the funds to support the company’s commercial launch […]

Read More
8 February, 2021

Ally Bridge Portfolio News – Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III

Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT” Nautilus Biotechnology is expected to receive $350 million in proceeds through the business combination, including a $200 million fully committed PIPE […]

Read More
3 February, 2021

Syapse Announces $68 Million Strategic Investment with Ally Bridge Group and Northpond Ventures to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network

February 02, 2021 10:00 ET — Financing to support expanded partnering opportunities with life sciences, health systems, regulators and molecular labs — — Syapse committed to delivering real-world insights to improve outcomes for people with cancer — SAN FRANCISCO and NEW YORK and HONG KONG, Feb. 02, 2021 (GLOBE NEWSWIRE) — Syapse®, a leading real-world evidence company […]

Read More
18 December, 2020

Ally Bridge Portfolio News – Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial

Hua Medicine (the”Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: ● Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of the COVID-19 global pandemic on time and with high quality data and results […]

Read More